Glaxo: Getting leaner - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Glaxo: Getting leaner

Jul 30, 2003

MNC Pharma major, GlaxoSmithKline (GSK), has improved its topline during the June quarter. After registering a 2.5% topline dip in the March quarter, the company has reported over 10% growth in the same during the June quarter. The company had attributed the topline dip in the March quarter to VAT concerns. Going by the June quarter performance it seems that the domestic pharma industry is back on track.

(Rs m)2QFY032QFY04Change1HFY031HFY04Change
Net Sales2,7343,01510.3%5,3905,6034.0%
Other Income9613541.4%16523039.3%
Total expenditure2,1452,2685.7%4,4214,357-1.4%
Operating Profit (EBDIT)58974726.7%9691,24628.6%
Operating Profit Margin (%)21.5%24.8% 18.0%22.2% 
Profit before Tax63883831.3%1,0401,38933.5%
Extraordinary items-2123--32123-
Profit after Tax/(Loss)40664859.7%63699957.1%
Effective tax rate (%)36.1%37.4% 35.8%36.9% 
Net profit margin (%)14.8%21.5% 11.8%17.8% 
No. of Shares (eoy) (m)74.574.5 74.574.5 
Earnings per share*21.834.8 17.126.8 
Current P/e ratio 11.7  15.2 

Its core business of pharmaceuticals (over 80% of sales) reported 5.7% growth during first half of 2003, much above the industry growth rate of 2.5% during the period. Export sales during the half year declined by 47% mainly due to the discontinuation of Ranitidine exports post the Ankleshwar site closure. This had an impact on the company’s overall sales performance during the half year. Its other businesses recorded a drop of 12% in sales during six months. Consequently, GSK finished 1HFY04 with only a 4% topline growth (excluding excise).

Improving efficiencies continued to help GSK post higher operating margins. Though in the June quarter, material cost as a percentage of sales did see an uptick, for the overall first half of the year material cost as a percentage of sales stayed below 48% (49.3% in 1HFY03). The company's focus on power brands that are more profit making (i.e. not under DPCO) seems to be yielding results. In FY03, the company's operating margins had improved by over 6% at 16.6%. Continuing the trend, operating margins have improved from 18% to over 22% in the first half of FY04. Consequently, GSK finished 1HFY04 with a 34% growth at the PBT levels.

Segment revenue break-up
(Rs m)2QFY032QFY04Change1HFY031HFY04Change
Others businesses594564-5.0%1,1771,036-12.0%
Total segment revenue3,1473,3235.6%6,0586,1982.3%

Post the merger with SmithKline, GSK has increasingly looked to close down unviable plants and also looked to increase outsourced manufacturing. It is looking at selling off property (of erstwhile SmithKline) and streamlining operations of both companies for optimal utilisation (through VRS). Consequently, the company's depreciation provisioning too has come down. The spurt in other income suggests that it is reaping the benefits of investible funds. GSK Consumer's estimated surplus cash stands at nearly Rs 2 bn.

Segment (PBIT) break-up
(Rs m)2QFY032QFY04Change1HFY031HFY04Change
Others businesses82899.7%167158-5.2%
Gross PBIT69283620.7%1,1271,37622.1%
Add: Interest income (net)1149362.9%2491273.3%
Less: Unallocable exp. (net)-65-46--112-78-
Total PBIT63883831.3%1,0401,38933.5%

The extraordinary items mentioned in 1HFY04 represents Rs 123 m received as profit on sale of its Bangalore office property. The company is also in the process of selling its Mumbai property, which is estimated to fetch the company nearly Rs 1 bn over the next few quarters.

At the current price of Rs 385, the stock is trading at a P/E multiple of 14.4x its annualised 1HFY04 earnings. The company is gearing itself towards 2005, when the patent regime comes into force. The company is also likely to finalise the much awaited merger with Burroughs Wellcome soon.

Equitymaster requests your view! Post a comment on "Glaxo: Getting leaner". Click here!


More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Nov 29, 2021 (Close)


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks